Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM,and/or 13q14 |
| |
| Affiliation: | 1. Division of Hematopathology, Department of Pathology, University of Miami, Miami, FL;2. Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL;3. Department of Molecular and Cellular Pharmacology, University of Miami, Miami, FL;1. Thoracic Oncology Research Group, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN;2. Division of Epidemiology and Biostatistics, School of Public Health, University of Memphis, Memphis, TN;3. Trumbull Laboratories, LLC/Pathology Group of the Mid-South, Memphis, TN;1. Department of Pathology, West China Second University Hospital, Sichuan University, 610041, Chengdu, Sichuan Province, People''s Republic of China;2. Department of Anatomy and Histology, Chengdu Medical College, 610083, Chengdu, Sichuan Province, People''s Republic of China |
| |
| Abstract: | Leukemic, non-nodal mantle cell lymphoma (MCL) is a relatively indolent disease characterized by asymptomatic leukemic presentation, non-nodal disease distribution, and slow disease progression, particularly in comparison to that of classic nodal MCL. We studied 3 cases of leukemic, non-nodal MCL in which TP53, ATM, and/or 13q14 deletions were identified. All three patients had disease progression leading to treatment requirements in two of the patients at 5 and 18 months after initial diagnosis. The third patient also clinically progressed 25 months after initial diagnosis but was lost to follow up despite recommendation for initiation of therapy. We present these cases as potential evidence that while leukemic non-nodal MCL is typically an indolent disease compared to classically defined mantle cell lymphoma, cytogenetic heterogeneity exists and cases with TP53, ATM, and/or 13q14 deletions may have a relatively aggressive clinical course. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
